Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Candel Therapeutics
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 3, 2026
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 21, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
May 20, 2026
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 15, 2026
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
February 13, 2026
←
Previous Page
1
2